Save time and jump to the most important pieces.
Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by the National Cancer Institute, AstraZeneca and Merck OCALA, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted key clinical, regulatory and corporate milestones achieved over 2024 and outlined its expected upcoming milestones. "It is clear that 2024 was a foundational year for AI
OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated December 11, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. This is an issue previously disclosed in our most recent Report on Form 10-Q. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(ii) requires a listed company to have stockholde
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company's incumbent directors – Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – to the Board of Directors (the "Board") at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") held today. Additionally, Ted D. Kellner was elected to the Board. Dr. William M. Mitchell, Chairman of the Board, stated: "We would like to sincerely thank our shareholders for their support and engagement throughout this process and are grateful for their trust in our clinical development strategy. The AIM Board i
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Invest
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the second quarter 2024. As previously announced, the Company will host a conference call and webcast today, Friday, August 16, 2024, at 8:30 AM ET (details below). "We continue to see great potential in Ampligen as we progress across our clinical development programs and look forward to results from our ongoing studies in the near
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, the "Kellner Group Nominees") today issue the following press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE:AIM). The Kellner Group is pleased to announce that Dr. William A. Carter, M
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)